

# Inflammation and Immunity in Stroke



**Anna M. Planas**

*Cerebrovascular Research Laboratory*  
IIBB-CSIC, Hospital Clínic, IDIBAPS  
Barcelona, Spain



Canadian Stroke Congress,  
Ottawa  
3th October 2011







Anna M. Planas

***DISCLOSURES: none***

“In the last two years, I have not had a financial interest/arrangement or affiliation with one or more organizations that could be perceived as a real or apparent conflict of interest in the context of the subject of this presentation.”




# STROKE



# The inflammatory cascade after brain ischemia

- 1) Reaction of resident cells: glial reaction
- 2) Adhesion and infiltration of leukocytes
- 3) Molecular players: cytokines, chemokines, adhesion molecules, TLR, complement...

Rojas et al, 07  
*JCBF* 27:1975




# Inflammatory markers as clinical predictors of outcome

- Eritrocyte sedimentation rate
- C Reactive protein (CRP)
- Interleukin-6 (IL-6)
- Tumor necrosis factor (TNF)
- Intercellular adhesion molecule (ICAM-1)


## Low plasma levels of IL-10 predict bad outcome and neurological impairment

Vila et al. (2003) *Stroke*



## High plasma levels of IL-6 and TNF- $\alpha$ predict bad outcome and neurological impairment

Castellanos et al. (2002) *Stroke*




Mean  $\pm$  SD delay to sampling  $8.2 \pm 5.7$  hrs

■ Lacunar stroke (n=113) ■ Controls (n=43)


# How is inflammation triggered after stroke??



Matzinger P, 2007  
Nat Immunol



Kariko et al 2004 *JCBF* 24:1288





**Ischemia induces danger signals activating the innate immune system**

Innate Immunity  
Cell Associated Receptors


# TLR expression increases after ischemia

(Perez-de Puig et al., unpublished)





# TLR-4 contributes to the brain lesion after ischemia in mice

Caso et al., *Circulation*. 2007




# TLRs in monocytes of stroke patients



Urrea et al., *Stroke* 2009



# How does innate immune receptor activation contribute to inflammation?



VCAM-1



Justicia et al., 2006  
*J Cereb Blood Flow Metab.* 26:421-32


# The Complement System responds to stroke

The complement system is activated in rodents after brain ischemia

De Simoni et al., 2004, *Am J Pathol* 164:1857-63

The complement system is activated in patients with acute stroke

Mocco et al., 2006, *Neurosurgery* 59:28-33 and *Circ Res* 99:209-17



# The Lectin Pathway



## Experimental

### ischemia/reperfusion in

### Manose-Binding Lectin (MBL)

### null and wt mice

2-h MCAO +48h reperfusion in mice WT / MBLnull




# The Lectin Pathway in stroke patients

## Manose-Binding Lectin (MBL) : MBL-sufficient and MBL-low genotypes

**Baseline characteristics in the study population (n=135) according to MBL genotype**



	<b>MBL-low N=24 (18%)</b>	<b>MBL-sufficient N=111 (82%)</b>	<b>p value</b>
Age (mean, SD), yrs	73.9 (12.8)	72.9 (11.5)	0.67
Male, no.(%)	9 (37.5)	59 (53.2)	0.16
Active smoking, no. (%)	3 (12.5)	20 (18.0)	0.77
Hypertension, no. (%)	12 (50.0)	73 (65.8)	0.15
Diabetes, no. (%)	6 (25.0)	24 (21.6)	0.72
Coronary heart disease, no. (%)	2 (8.3)	15 (13.5)	0.49
Previous stroke, no. (%)	4 (16.7)	19 (17.1)	1.00
Peripheral artery disease, no. (%)	2 (8.3)	9 (8.1)	1.00
Admission NIHSS score, no. (%)			0.10
	0 to 6	5 (21)	14 (13)
	7 to 17	13 (54)	56 (51)
	>17	6 (25)	41 (37)

# Stroke patients



**60% MBL-low and 30% MBL-sufficient patients reached functional independence (mRS score 0 to 2) ( $\chi^2, p=0.008$ )**

**% GOOD OUTCOME AT 3 MONTHS**




# The complement can activate the coagulation cascade favoring secondary vessel occlusion

## Coagulation activates complement:


- Platelets phosphorylate C3b and cleave C3
- Trombin and factor XIIa: cleave C3, C5

## Complement has Procoagulant activity:

- Induces platelet activation
- ↑ Cellular TF expression (C5)
- Modifies phospholipid membranes and facilitates the extrinsic coagulation pathway (TF)



In infections, complement induces local thrombus formation as a barrier to prevent bacterial dissemination in the circulation



Takahashi et al., 2011, *Immunobiology* 216:96–102

Endo et al., 2009 *J Innate Immun* 2:33-42

## Complement and coagulation: strangers or partners in crime?

Markiewski et al., *TRENDS Immunol* 2007




Review


TRENDS in Immunology Vol.28 No.4

TRENDS in Immunology

# The cross-talk between the CNS and the immune system: *stroke-induced immunodepression facilitates infection*




Prass et al, *J Exp Med*, 2003





Prass et al, *Stroke*, 2006

Martin et al., *Mol Imaging*, 2008




Offner et al, *J Immunol*, 2006





Chamorro et al, *Stroke*, 2007


# Lymphocytes



## Apoptosis








# Monocytes




Phenotype

Function



# Monocyte subtypes




**CD16:** “bad guys” inflammation  
cancer

**CD14:** main subtype


Phenotype	CD14 <sup>high</sup> CD16 <sup>-</sup>	CD14 <sup>dim</sup> CD16 <sup>+</sup>	CD14 <sup>high</sup> CD16 <sup>+</sup>
Frequency	85%	10%	5%
Function	Inflammation	TNF- $\alpha$ Non-inflamed tissues	IL-10

# Monocyte subtypes after stroke

## Phenotype




Urra et al (2009) J Cereb Blood Flow Metab;  
 Urra et al (2009) Stroke




□ CD14<sup>high</sup>CD16-   
 ■ CD14<sup>high</sup>CD16+   
 ■ CD14<sup>dim</sup>CD16+

## Platelet-monocyte complexes



## Infection







**Early worsening      Poor prognosis      Mortality**

CD14<sup>h</sup>CD16-, OR

**1,29**

**1,38**

**1,40**



The organism becomes aware of brain damage and reacts to it through the immune system. The innate immune system is quickly activated and mediates secondary reactions.

**But how and why???**


**Initiation of damage resolution and repair???**

# Certain immune responses can alter mechanisms of protection and repair


## Inflammation and innate immunity in neurogenesis

Deficiency in TLR4 in the early postnatal retina results in increased neuronal differentiation

*Shechter et al 08 J Cell Biol 183:393*




## Complement affects neurogenesis and regeneration



*Rutkowski et al., Immunol Cell Biol. 2010*

## Regulatory T cells protect the brain after stroke



*Liesz et al, Nat Med, 2009; Planas & Chamorro, Nat Med, 2009*

**CD14++CD16+Tie2+ monocytes**

Phagocytosis / Angiogenesis

Protective effects in myocardial ischemia

*Nahrendorf et al, J Exp Med, 2007*  
*Tsujioka et al, JACC, 2009*


# Therapeutic strategies

## Modulate post-stroke immune responses

Downregulate deleterious responses and enhance protective mechanisms

- Attenuate lymphocyte activity
- Promote the action of regulatory lymphocytes
- Prevent complement activation
- Limit proinflammatory cytokines
- Favour antiinflammatory cytokines
- Promote recovery
- Antibiotics
- Combine immunomodulatory and thrombolytic therapies

**Will effective treatments in experimental ischemia translate into the clinic?**



# Conclusions

- Innate immunity plays an active role in inflammation and brain damage after stroke
- Genetics may affect the features and magnitude of inflammatory and/or immune responses: towards a more personalised treatment?
- Stroke induces a transient immunodepression that favours systemic infections
- The study of blood cells can improve our understanding of the interactions between brain and immune system in stroke
- The modulation of specific immunological targets offers new therapeutic avenues that are being explored
- Inflammation and innate immunity affect neurogenesis and repair. Understanding the intensity of the signals and their time course is essential for the design of novel therapeutic strategies.

# Cerebrovascular Research Laboratory

IIBB-CSIC, Hospital Clínic, IDIBAPS, Barcelona, Spain



Angel Chamorro  
Xabier Urra  
Alvaro Cervera

Isabel Pérez de Puig  
Carles Justicia  
*Roser Gorina*

